Specifications Table {#s0005}
====================

TableSubject area*Biology*More specific subject area*Epigenetics and Toxicology*Type of dataText, raw data filesHow data was acquiredInfinium Methylation EPIC Bead Chip Methylation ArrayData format*Raw, filtered*Experimental factors*HeLa cells were exposed to 0.5 µM sodium arsenite, mimicking the levels of arsenic in the water supply of Eastern Kentucky (in particular). Cells that had undergone the epithelial-to-mesenchymal transition from inorganic arsenic exposure then had the sodium arsenite removed and continued to be grown to see if the removal of the environmental toxicant could reverse some of the methylation and gene expression changes observed. Non-treated HeLa cells were used as a control to which DNA methylation changes could be compared.*Experimental features*We analyzed DNA methylation changes genome-wide by profiling HeLa cells that were exposed to 0.5 µM sodium arsenite, as well as cells that were treated and had arsenic removed using the methylation array.*Data accessibility*Microarray data has been deposited into the NCBI GEO database (Accession number*[GSE95232](ncbi-geo:GSE95232){#ir0005}*)*

**Value of the data** {#s0010}
=====================

•Genome-wide assessment of DNA methylation changes in inorganic arsenic-mediated epithelia-to-mesenchymal transition cells and reversal of inorganic arsenic-treated cells.•DNA methylation profiling in cells in response to chronic, low dose inorganic arsenic exposure.•Implication of DNA methylation as an epigenetic contributor to inorganic-arsenic mediated epithelial-to-mesenchymal transition.•Valuable for understanding genome-wide epigenetic implications of chronic, low dose exposure to inorganic arsenic, a common environmental toxicant.

1. Data {#s0015}
=======

The Infinium Methylation EPIC BeadChip Array profile data are provided as MINiML and TXT files deposited into NCBI GEO, accession number [GSE95232](ncbi-geo:GSE95232){#ir0010}. Genomic DNA was extracted from non-treated, inorganic arsenic-treated, and inorganic arsenic reverse-treated HeLa cells, bisulfite converted, and applied to the BeadChip Array. Two replicates of each sample were performed. The BeadChip Array detected DNA methylation status genome wide of non-treated, inorganic arsenic-treated, and inorganic arsenic reverse-treated HeLa cells. Gene ontology analysis of the differentially methylated genes revealed that many of the genes had oncogenic signatures according to the Gene Set Enrichment Analysis ([Supplemental Tables 1--3](#s0050){ref-type="sec"}). Specifically, many of them are connected to KRAS signaling in several types of cancer in epithelial cells such as those of the lung, breast, and kidney tissues. A more complete description of this data can be found in Eckstein et al. (2017) [@bib1].

2. Experimental design, materials and methods {#s0020}
=============================================

2.1. HeLa cell growth conditions and treatment {#s0025}
----------------------------------------------

HeLa cells were grown as previously described in [@bib3], [@bib4]. Reverse-treated cells were treated with 0.5 µM sodium arsenite for 36 days, at which point they were treated with water instead of sodium arsenite (reverse-reated cells). These reverse-treated cells were harvested 10 days after reversal of treatment.

2.2. Infinium MethylationEPIC Bead Chip -- methylation array analysis {#s0030}
---------------------------------------------------------------------

*Sample preparation*. Genomic DNA from non-treated, treated, and reverse treated cells was extracted using the Qiagen DNeasy Blood and Tissue kit. DNA was initially bisulfite converted using the Zymo EZ-96DNA Methylation Kit (Catalog \#D5004) Deep-Well Format. DNA was treated with sodium bisulfilte causing unmethlylated cytosines to convert to uracil while keeping methylated cytosines unchanged. Then 4ul (equivalent to 750 ng DNA) of the bisulfite converted DNA was used as input for the Illumina Infinium HD Methylation Array. During this process, the bisulfite converted DNA samples were denatured, neutralized, and prepared for amplification. After amplification, the amplified DNA was enzymatically fragmented and precipitated. The resuspended DNA samples were then dispensed onto Illumina׳s Infinium MethylationEPIC BeadChip, where they underwent a series of washing, extension, and staining procedures. The BeadChips are then coated for protection and scanned on the Illumina HiScanHQ. Once scanning is completed, the data is uploaded into GenomeStudio for preliminary analysis and QC.

2.3. Data analyses {#s0035}
------------------

For statistical analysis, beta values were calculated. The methylation levels of CpGs were described as beta values (0--1) representing the calculated level of methylation (0--100%). We had two technical and two biological replicates processed by chip technique. The Pearson correlation coefficients (PCCs) were \>0.99 for all the replicates, confirming a good level of reproducibility for the chip process and indicating that the observed differential methylation between the cells (treatments) represented true biological differences. Functional normalization was performed using home scripts 'Minfi preprocessFunNorm' which does the background normalization. Additionally, the dye correction was performed using noob. All CpG sites with detection value\>0.05, CpG sites with SNPs, as well as probes predicted to hybridize to more than one genomic location [@bib2] were removed.

Appendix A. Supporting information {#s0050}
==================================

Supplementary data associated with this article can be found in the online version at [10.1016/j.dib.2017.05.002](http://dx.doi.org/10.1016/j.dib.2017.05.002){#ir0007}.

Transparency document. Supplementary material {#s0045}
=============================================
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